{"article_title": "New Costly Cancer Treatments Face Hurdles Getting to Patients", "article_keywords": ["hurdles", "therapeutics", "costly", "target", "cancer", "getting", "trials", "separate", "treatments", "face", "patients", "clinical", "shown", "switzerland", "trialssponsored"], "article_url": "http://www.wsj.com/articles/new-costly-cancer-treatments-face-hurdles-getting-to-patients-1412627150", "article_text": "Cancer treatments that genetically modify patients\u2019 blood cells to target the disease have shown amazing results in clinical trials. Now drug companies and biotechs must overcome big hurdles to get them into hospitals, including their potential cost.\n\nIn two separate clinical trials\u2014sponsored by Novartis AG of Switzerland and Seattle-based biotech Juno Therapeutics Inc.\u2014almost 90% of patients saw their leukemia disappear after being...", "article_metadata": {"article.template": "snippet", "article.created": "2014-10-06T20:25:00.000Z", "article.section": "Business", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "Cancer treatments that genetically modify patients\u2019 blood cells to target the disease have shown amazing results in trials. Now drug companies and biotechs must overcome big hurdles to get them into hospitals, including their potential cost.", "title": "New Costly Cancer Treatments Face Hurdles Getting to Patients", "image": {"src": "https://si.wsj.net/public/resources/images/OG-AC738_201410_G_20141006170117.jpg", "alt": "New cancer treatments face hurdles\u2014including big costs\u2014getting to patients", "identifier": "https://si.wsj.net/public/resources/images/OG-AC738_201410_D_20141006170117.jpg"}, "creator": "@hesterplumridge", "site": "@WSJ", "card": "summary_large_image"}, "al": {"ios": {"url": "wsj://launch?articleid=SB10001424052970203898604580147700925205526&headline=New%20cancer%20treatments%20face%20hurdles%u2014including%20big%20costs%u2014getting%20to%20patients&weburl=http://www.wsj.com/articles/SB10001424052970203898604580147700925205526"}}, "page.site.product": "WSJ", "keywords": "cancer,cancer treatments,car t-cell therapy,immunotherapy,leukemia,lymphoma,Novartis,NOVN.VX,NVS,Juno Therapeutics,Cellectis,ALCLS.FR,Bluebird Bio,BLUE,Kite Pharma,KITE,Dr. Daniel DeAngelo,Mikael Dolsten,Malcolm Brenner,Hans Bishop,Stephen McGarry,Usman Azam,new products,services,research,development,corporate,industrial news,new product,service testing,political,general news,health,medical conditions,medical treatments,procedures,pharmaceuticals,medical equipment,supplies,health care,life sciences,medical,surgical instruments,apparatus,devices,therapeutic devices,equipment", "news_keywords": "cancer,cancer treatments,car t-cell therapy,immunotherapy,leukemia,lymphoma,Novartis,NOVN.VX,NVS,Juno Therapeutics", "article.headline": "New cancer treatments face hurdles\u2014including big costs\u2014getting to patients", "cXenseParse": {"candybar": {"image": "https://si.wsj.net/public/resources/images/OG-AC738_201410_E_20141006170117.jpg"}, "poptart": {"image": "https://si.wsj.net/public/resources/images/OG-AC738_201410_D_20141006170117.jpg"}}, "description": "Cancer treatments that genetically modify patients\u2019 blood cells to target the disease have shown amazing results in trials. Now drug companies and biotechs must overcome big hurdles to get them into hospitals, including their potential cost.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB10001424052970203898604580147700925205526&headline=New%20cancer%20treatments%20face%20hurdles%u2014including%20big%20costs%u2014getting%20to%20patients&weburl=http://www.wsj.com/articles/SB10001424052970203898604580147700925205526", "user.type": "nonsubscriber", "testkeys": "A", "article.page": "Business", "article.summary": "Cancer treatments that genetically modify patients\u2019 blood cells to target the disease have shown amazing results in trials. Now drug companies and biotechs must overcome big hurdles to get them into hospitals, including their potential cost.", "page.site": "wsj", "page.content.format": "responsive", "article.published": "2014-10-06T20:25:00.000Z", "dj.asn": "i-f265", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"publisher": "https://www.facebook.com/wsj", "embed_count": 1, "image_count": 1, "word_count": 965, "internal_link_count": 1}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "Cancer treatments that genetically modify patients\u2019 blood cells to target the disease have shown amazing results in trials. Now drug companies and biotechs must overcome big hurdles to get them into hospitals, including their potential cost.", "title": "New Costly Cancer Treatments Face Hurdles Getting to Patients", "url": "http://www.wsj.com/articles/new-costly-cancer-treatments-face-hurdles-getting-to-patients-1412627150", "image": {"width": 553, "identifier": "https://si.wsj.net/public/resources/images/OG-AC738_201410_G_20141006170117.jpg", "height": 369}, "locale": "en_US", "type": "article"}, "author": "Hester Plumridge", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "New Costly Cancer Treatments Face Hurdles Getting to Patients", "article.type": "Business", "article.id": "SB10001424052970203898604580147700925205526", "user.exp": "default", "article.updated": "2014-10-06T20:25:00.000Z"}, "_id": "\"57477af46914bd0286fde0ea\"", "article_summary": "Cancer treatments that genetically modify patients\u2019 blood cells to target the disease have shown amazing results in clinical trials.\nIn two separate clinical trials\u2014sponsored by Novartis AG of Switzerland and Seattle-based biotech Juno Therapeutics Inc.\u2014almost 90% of patients saw their leukemia disappear after being...\nNow drug companies and biotechs must overcome big hurdles to get them into hospitals, including their potential cost."}